阅读说明：本技术 使用包含parp抑制剂、替莫唑胺和/或放射疗法的组合治疗癌症 (Treatment of cancer using a combination comprising a PARP inhibitor, temozolomide and/or radiation therapy ) 是由 汪来 汤志宇 罗吕松 魏旻 A·彼得森 王鹤翔 任博 周昌友 于 2018-07-17 设计创作，主要内容包括：本文公开了用于在受试者中预防癌症、延缓癌症的进展或治疗癌症的方法,该方法包括向有需要的受试者给予PARP抑制剂,具体地(R)-2-氟-10a-甲基-7,8,9,10,10a,11-六氢-5,6,7a,11-四氮杂环庚并[def]环戊并[a]芴-4(5H)-酮、其倍半水合物或其药学上可接受的盐与替莫唑胺和/或放射疗法的组合。另外,公开了药物组合及其用途,该药物组合包含PARP抑制剂,具体地(R)-2-氟-10a-甲基-7,8,9,10,10a,11-六氢-5,6,7a,11-四氮杂环庚并[def]环戊并[a]芴-4(5H)-酮、其倍半水合物或其药学上可接受的盐与替莫唑胺的组合。(Disclosed herein are methods for preventing, delaying progression of, or treating cancer in a subject, comprising administering to a subject in need thereof a PARP inhibitor, in particular (R) -2-fluoro-10 a-methyl-7, 8,9,10,10a, 11-hexahydro-5, 6,7a, 11-tetraazacyclohepta [ def ] cyclopenta [ a ] fluoren-4 (5H) -one, a sesquihydrate thereof, or a pharmaceutically acceptable salt thereof, in combination with temozolomide and/or radiation therapy. In addition, pharmaceutical combinations comprising a PARP inhibitor, in particular a combination of (R) -2-fluoro-10 a-methyl-7, 8,9,10,10a, 11-hexahydro-5, 6,7a, 11-tetraazacyclohepta [ def ] cyclopenta [ a ] fluoren-4 (5H) -one, a sesquihydrate thereof or a pharmaceutically acceptable salt thereof and temozolomide, and uses thereof are disclosed.)